logo
Plus   Neg
Share
Email

Jounce Therapeutics Inc. (JNCE) Has Tumbled To A New Low For The Year

Jounce Therapeutics Inc. (JNCE) reported preliminary results from its ongoing Phase 1/2 trial of JTX-2011 alone and in combination with nivolumab in patients with advanced solid tumors Monday morning.

Jounce Therapeutics gapped open sharply lower Monday morning and is now down 3.23 at $8.00 in early trade. The stock has tumbled to a new low for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

RELATED NEWS
Follow RTT
>